Management of infertility in women with hypothalamic hypogonadotropic hypogonadism: an expert opinion.

Industry-sponsored "expert opinion" recommends gonadotropins + hCG luteal support when pulsatile GnRH therapy is unavailable — no original data included

Journal: Reproductive Biology and Endocrinology | Published: 2026-02-19 | Type: Review / Expert Opinion | PMID: 41715131 Authors: Robin Geoffroy (CHU Lille), Lorraine Maitrot-Mantelet (Paris Center University Hospital), Sophie Dubourdieu (Atlantic Polyclinic, Nantes), Bérengère Kiehl-Bigot (Ferring SAS), Maria Katsogiannou (ICTA PM), Michel De Vos (Brussels IVF), Sophie Christin-Maitre (Paris) Funding/COI: Funding not disclosed. Geoffroy: consulting/speaker fees from Merck, IBSA, Gedeon Richter, Ferring. Maitrot-Mantelet: consulting/speaker fees from Gedeon Richter, Besins, Ferring, Exeltis. Kiehl-Bigot is a Ferring employee. Katsogiannou is an employee of ICTA PM — the organization to which article writing was subcontracted. Dubourdieu and Christin-Maitre declare no conflicts.

Summary

This is an expert consensus review, not a study — it contains no original data. It describes how pulsatile GnRH therapy is the physiologically ideal treatment for female hypothalamic hypogonadotropic hypogonadism (HH), then lays out a fallback protocol using exogenous gonadotropins plus hCG luteal support for when GnRH devices are unavailable. The recommendations are opinion-level guidance dressed in review formatting, and one of the companies whose products are recommended employs two of the paper's named authors.

Claims

• Pulsatile GnRH therapy is framed as the gold standard for restoring ovulation in women with congenital hypothalamic HH (CHH) and functional hypothalamic amenorrhoea (FHA), citing "high ovulation rates and consequently high pregnancy and birth rates per cycle" — no pooled numbers provided in the abstract
• When pulsatile GnRH is unavailable, exogenous gonadotropins are recommended, with starting doses and adjustments to vary by HH aetiology
• Luteal phase support with hCG injections is described as "imperative" and "mandatory" in all cases, to optimize corpus luteum function
• The review covers FHA with and without polycystic ovarian morphology (PCOM) as distinct sub-populations requiring differentiated dosing

Study Quality

This is an expert opinion piece, which sits at the bottom of the evidence hierarchy. There is no systematic literature search, no PRISMA flow diagram, no GRADE assessment of the recommendations, and no pre-registered protocol. The abstract does not specify how papers were selected or what criteria were used to elevate a recommendation from "suggested" to "mandatory." Clinical guidance issued without an explicit evidence grading system cannot be assessed for reproducibility or bias resistance.

The paper's stated purpose is to bridge a gap: pulsatile GnRH devices have faced availability issues in some markets. That is a legitimate clinical problem. But the bridge being offered here is expert opinion from a group with documented financial ties to the manufacturers of the alternative treatments being recommended.

Red Flags

• Article writing was subcontracted to ICTA PM, a medical communications firm, whose employee (Katsogiannou) is listed as an author — this is ghost/contract writing with authorship attribution, a practice condemned by ICMJE guidelines
• Ferring employee is an author (Kiehl-Bigot); Ferring manufactures Lutrelef (pulsatile GnRH) and gonadotropin products — direct financial interest in both the "gold standard" and the "fallback" being recommended
• Multiple authors hold consulting and speaker fees from Merck, IBSA, Gedeon Richter, Ferring, Besins, Theramex, and Exeltis — several of which market the exact gonadotropins discussed
• No funding source is listed despite the industry authorship and contract writing arrangement
• No quantitative evidence synthesis — effect sizes, pregnancy rates, and ovarian hyperstimulation (OHSS) risk figures are referenced vaguely in the background, not tabulated
• Recommendations labeled "mandatory" and "imperative" without citing the RCT or meta-analytic evidence that would justify that certainty

Strengths

• Addresses a real clinical gap: pulsatile GnRH devices have genuine availability constraints in some health systems
• Covers multiple HH subtypes (CHH, FHA, FHA+PCOM) as distinct populations rather than collapsing them
• Published in a peer-reviewed journal with COI disclosures, at least making the conflicts visible rather than hidden

Verdict

The conflict of interest structure here is about as loaded as it gets: the article was written by a contractor, one of whose employees is listed as an author alongside a Ferring pharmaceutical employee, and the resulting "expert opinion" recommends products sold by companies paying several of the remaining authors consulting and speaker fees. That does not automatically make the clinical guidance wrong — pulsatile GnRH shortage is a documented problem and gonadotropin protocols are established — but it makes this paper's specific dosing recommendations and its characterization of certain interventions as "mandatory" entirely untrustworthy as independent guidance. Read it as an industry position paper, not a neutral clinical review.